VistaGen Therapeutics, Inc.
VTGN
$0.61
-$0.02-3.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 17.44% | 5.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.44% | 5.74% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 17.44% | 5.74% | |||
| SG&A Expenses | 27.98% | 0.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.27% | 26.56% | |||
| Operating Income | 2.53% | -26.89% | |||
| Income Before Tax | 2.67% | -28.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.67% | -28.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.67% | -28.63% | |||
| EBIT | 2.53% | -26.89% | |||
| EBITDA | 2.54% | -26.87% | |||
| EPS Basic | 17.60% | -14.89% | |||
| Normalized Basic EPS | 17.61% | -14.89% | |||
| EPS Diluted | 17.60% | -14.89% | |||
| Normalized Diluted EPS | 17.61% | -14.89% | |||
| Average Basic Shares Outstanding | 18.14% | 11.96% | |||
| Average Diluted Shares Outstanding | 18.14% | 11.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||